Skip to main content

Table 4 Median progression free survival time in the studies

From: The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis

Study Median progression free survival time(months) Median ratio pvalue
  TS +/high TS -/low   
Bepler et al. [6] 20.7 21 1.01 0.187
Chang et al. [29] 1.3 2.4 1.85 0.407
Chen et al. [21] 3.4 4.8 1.41 0.01
Sun et al. [17] 2 4.1 2.05 0.001
Igawa et al. [30] 1.6 5.8 3.63 0.03
Pool 5.8 7.6 1.31
(95% CI 0.43-2.19)
0.13
  1. Patients with +/high expression of TS who received pemetrexed-based chemotherapy had a median progression free survival time of 5.8 months; patients with -/low expressionof TS had a median progression free survival time of 7.6 months. Although there was a trend that TS -/low predicted better progression free survival time, the difference did not reached statistical significance (p = 0.13).